Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy

Similar documents
Donor work up, follow up and ethical issues

Spanish Donor Registry. Follow-Up Data

LEGISLATIVE FRAMEWORKS AND ETHICS OF DONATION. Jeff Szer, Royal Melbourne Hospital, Australia

Accreditation of BMT units & EU Regulations

Blood and Marrow Transplant (BMT) for Sickle Cell Disease

Sickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?

Global Perspective on Donor and Recipient Safety: Biovigilance in Hematopoietic Cell Transplantation

Dr.PSRK.Sastry MD, ECMO

COHEM Barcellona 2012 Hemoglobinopathies debate

Post Transplant Management for Sickle Cell. Title

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

BMTCN REVIEW COURSE PRE-TRANSPLANT CARE

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Back to the Future: The Resurgence of Bone Marrow??

Rationale for RBC Transfusion in SCD

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

SICKLE CELL DISEASE. Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH. Assistant Professor FACULTY OF MEDICINE -JAZAN

Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

Bone Marrow Transplantation and the Potential Role of Iomab-B

Hematopoietic Stem Cell Therapy

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

An Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD

STEM CELL TRANSPLANT IN PEDIATRICS. Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17

1 Kattamis et al. Growth of Children with Thalassemia: Effect of Different Transfusion Regimens. Archives of

"Chemotherapy based stem cell mobilization: pro and con"

Haematopoietic stem cell transplantation (SCT)

An Introduction to Bone Marrow Transplant

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Hematopoietic Stem Cells

Bor-Sheng Ko. Hematology Division, Department of Internal Medicine, National Taiwan University Hospital

DEPARTMENT OF CLINICAL HEMATOLOGY

Hematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum

Need considerable resources material and human.

Transplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust

Granix. Granix (tbo-filgrastim) Description

Plerixafor: mechanism of action

Granix. Granix (tbo-filgrastim) Description

AABB Standards and Accreditation. Doug Padley, MT (ASCP) Mayo Clinic Rochester MN USA

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

Granix. Granix (tbo-filgrastim) Description

Sickle cell disease. Fareed Omar 10 March 2018

APHERESIS PROCEDURES. Worldwide implemented nowadays. Most of Asian Countries also involved. The usage of this procedure varies between countries.

Bone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa

Granix. Granix (tbo-filgrastim) Description

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Developing a Quality Dashboard An Evidence Based Approach PURPOSE/OBJECTIVES:

An Overview of Blood and Marrow Transplantation

CELLULAR THERAPY QUIZ. Correct answers and rationale

Blood Components & Indications for Transfusion. Neda Kalhor

OPERATIONS AND PATIENT SERVICES USER GUIDE. Procedures for transplant centres and international establishments

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

4nd Patient and Family Day

Relevant Communicable Diseases in HCT/Ps

WAA/SFH Joint Congress

Guidance for establishing a hematopoietic progenitor cells donor follow-up registry

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Mobilization & Pre-Transplant Conditioning Regimens

& 2003 Nature Publishing Group All rights reserved /03 $

Hydroxyurea Treatment for Sickle Cell Disease

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Stem cell transplantation for patients with AML in Republic of Macedonia: - 15 years of experience -

Stem Cell Mobilization Protocols: Filgrastim vs. Mozobil

CLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98

FormsNet Adverse Event Form

OneMatch Stem Cell and Marrow Network. Training Guide

Anemia (3).ms Hemolytic Anemia. Abdallah Abbadi Feras Fararjeh

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Hematopoetic Stem Cell Therapies in TURKIYE

D7.1 Report summarising results of survey of EU countries to identify volumes and trends in relation to the import and export of stem cells

Dedicated to Gordon. Stem Cell Transplantation: The Journey

EZER MIZION PROCEDURES FOR TRANSPLANT CENTERS AND COOPERATIVE REGISTRIES

CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints

Introduction to Hematopoietic Stem Cell Transplantation

Donatore HLA identico di anni o MUD giovane?

Candidates must answer ALL questions

Transplants. Mickey B. C. Koh

Transition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology

Congenital Haemoglobinopathies

Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease

EBMT Society EBMT. History Organisation Studies Activity Philosophy. EBMT Website. European Group for Blood and Marrow Transplantation

Understanding the role of ex vivo T cell depletion

Blood and Marrow Transplantation for Haemoglobinopathies. Dr Josu de la Fuente St. Mary s Hospital London

RBC Transfusion

Are We There Yet? Gene Therapy and BMT as Curative Therapies in Sickle Cell. Ann Haight, MD 9 Sept 2017

Other labs 4/24/2012. N 24: Pediatric Hematological Alterations & Cancer Intro. Cabrillo College ADN Program C. Madsen RN, MSN 1.

Anemia s. Troy Lund MSMS PhD MD

Implementation of the Stem Cell Therapeutic and Research Act of 2005

HAEMATOPOIETIC STEM CELL TRANSPLANTATION

PEDIATRIC HEMATOLOGY/ONCOLOGY ROTATION

Recommended Timing for Transplant Consultation

A PRIMER ON APHERESIS MEDICINE

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

HIGHLIGHTS OF PRESCRIBING INFORMATION

Sickle Cell Disease. Edward Malters, MD

Late complications after hematopoietic stem cell transplant in adult patients

Voluntary Accreditation of Immune Effector Cell Programs

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

Transcription:

Regulatory Challenges in Apheresis Global Perspectives - Cell Therapy Joseph (Yossi ) Schwartz, MD, MPH Director, Transfusion Medicine & Cellular Therapy Columbia University Medical Center New York Presbyterian Hospital New York, NY

Objectives 1. Describe the different global cell therapy standards 2. Can we align those standards? 3. How can we comply with cell therapy standards case scenarios

Cell Therapy Standards Organization Accreditation Cycle AABB FACT JACIE FDA WMDA Two years Three years Four years Interval not set Five years

FACT Cellular Therapy & NetCord Accredited Facilities

JACIE Accredited Facilities SINGAPORE

AABB Accredited Facilities

Worldwide Location of Unrelated Donor Registries Petersdorf EW, BMT, 45, 807 8 (2010)

World Marrow Donor Association WMDA fosters international collaboration to facilitate the exchange of high quality haematopoietic stem cells for clinical transplantation worldwide and to promote the interests of donors. Global standards cover all aspects of unrelated hematopoietic stem cell registry operations.

NMDP Standards set forth basic guidelines and requirements for programs working with the NMDP. Standards encompass network participation criteria with requirements for transplant hospitals, recruitment centers, product collection centers, etc. Standards for the donation process; product collection, storage, transportation, processing and labeling; adverse events, complaints and non-conforming products.

Can We Align It All Together?

AHCTA mission statement: the above named organizations commit themselves to the harmonization of their respective standards with the objective of creating a single set of quality, safety and professional requirements for cellular therapy

AHCTA Donor Standards Comparison

Case 1 Healthy Allo Donor 8 yo HLA-matched sibling donor, sickle trait PMH: Non significant Physical Exam: No major concerns Plan: G-CSF 10 mg/kg/d; HPC collections by Apheresis on day 4&5 of G-CSF? Considerations for G-CSF & Apheresis?

Standard (1) AABB standards, 6 th edition, 2013 Standard 5.12.6.1 & similar FACT-JACIE standard: C6.3.3, 5 th edition, 2012: living allogeneic and autologous donors shall be evaluated for the risk of hemoglobinopathy before the administration of G-CSF Rationale behind?

Principal Axis for Retention, Migration, and Mobilization of HPCs HPC CXCR4 SDF-1a Bone Marrow SDF-1/CXCL12, secreted by BM stormal cells, binds to CXCR4 ligand, expressed on CD34+ HPCs

G-CSF Induced Mobilization

Mechanism of Action for Mobilization G-CSF Vs. AMD3100 (Mozobil) Gratwohl, A. et al. Blood 2008;112:923-924

G-CSF Complications in Sickle Cell Disease G-CSF can cause vaso-occlusive crisis with in pts with Hgb S/S, S/C or S/β thal 11 case reports of G-CSF use in SCD. 7 require hospitalization, while 4 others experienced no complications Multi-organ failure & death in one previously asymptomatic 47 yo donor with Hgb S/C Crises might be related to acute PMN and PMN activation Lancet 1998;351:959 Blood 2001;97:3313 Blood 2001;97:3998 Blood 2002;99:850 Blood Cells Mol Dis 2005;35 Cyotherapy 2009;11:464

Are Donors With Sickle Trait (Hb AS) at Increased Risk from G-CSF? Donors with sickle trait were safely mobilized and collected The sickle trait donors did have higher symptom score than control donors There were no symptoms suggestive of sickle crisis No difference in CD34 yield or in apheresis and processing procedures The risk is limited Kang et al, Blood 2002;99:850

Being Compliant w/the Standard (1) FACT/AABB Standards: living allogeneic and autologous donors shall be evaluated for the risk of hemoglobinopathy before the administration of G-CSF

Standard (2) FACT standards, 5th ed., 2012, Standard C8.5 & AABB standards, 6 th ed. 2013, 5.13.1: There shall be written documentation of an interim assessment of donor suitability for the collection procedure performed by a qualified person immediately prior to each collection procedure. Rationale behind?

Case 2 You are evaluating a 45 yo donor who is to donate G-CSF -Mobilized PBSC for her HLA matched sibling with AML. She already had 5 days of G-CSF and is about to start the collection Complaints of new abdominal pain with radiation to the left shoulder What are the concerns for this donor?

G-CSF and The Spleen Splenic Enlargement: Spleen size has been studied in over 100 healthy HPC, Apheresis donors In almost all donors: spleen volume and length increases 10-13% on average Begins to reverse quickly with a return to baseline within 10 days after completion of G- CSF Due to extramedullary hematopoiesis donor risk for splenic rupture Stroncek et al, Transfusion 2003;43:609 Platzbecker et al, Transfusion 2001;41:184

G-CSF and The Spleen Splenic Rupture: 11 cases of Splenic rupture reported to date in adult donors of HPC, Apheresis 1 (5 auto, 6 allo donors) The incidence is estimated to be 1:5,000-1:10,000 2 Splenic rupture has not been reported in children Histologic examination of the ruptured spleen: massive extramedullary hematopoiesis & subcapsular bleeding 1 Bone Marrow Transplant 2007;40:361 2 Pediatr Blood Cancer 2006;46:422

Splenic Rupture Common signs and symptoms: Nausea, malaise Pain radiating to left shoulder Blood Pressure Hematocrit Can happen anytime after initiation of G-CSF - most common between D5-10 Dincer et al. J Ped Hematol Oncol 2004; 26:761

Additional Serious Adverse Events Related to G-CSF Vascular events: MI, increase anginal episodes, CVA Flare of autoimmune disease: RA, AS, SLE, MS, Scleroderma, thyroid dysfunction (preexisting Antithyroid Abs) Eye inflammatory responses: keratitis, episcleritis, iritis Bone Marrow Transplantation 2007;39:577 JCA 2006;21:116 J Am Coll Cardiol 2005;46:1643 Hematology 2005:469 Careful screening of history Risk versus benefit Interim assessment of complaints

Being Compliant w/the Standard (2) FACT Standard C8.5 & AABB standard 5.13.1: There shall be written documentation of an interim assessment of donor suitability for the collection procedure performed by a qualified person immediately prior to each collection procedure.

Standard (3) FACT standards, 5th ed., 2012, Standard C8.5.1 & AABB standards, 6 th ed. 2013, standard 5.12.4: A complete blood count, including platelet count, shall be performed within 24 hours prior to each HPC collection by apheresis. C8.5.2: There shall be peripheral blood count criteria to proceed with collection. Rationale behind?

Case 3: Platelets & HPC,Apheresis collection 29 yo healthy male sibling donor mobilized with G-CSF 10 µg/kg/d Apheresis d4 G-CSF: 12 L; heparin + ACD-A temp 40 o C at procedure end; hospitalized Collection yield: 4.5 x 10 6 CD34+ cells/kg Fever resolved; no source identified F/U apheresis d10 after 1 st collection for DLI: severe platelet clumping noted abort

Plt Count x 10 9 /L Platelets & HPC,Apheresis collection 250 Start G-CSF preapheresis 200 150 100 50 postapheresis Days d6 d3 post-apheresis d10 DLI collection

Post Collection Donor Issues Platelets Each collection, a donor loses ~4x10 11 plt G-CSF can cause Plt count (usually mild) After one collection: Plt count ~30% BMT 1999;24:1273 Transf Apheresis Sci 2005;33:275 Hematology Am Soc Hematol Educ Program 2005:469

Platelets loss Autologous Collections Flommersfeld et al. Trans. Apher Sci 2013, 49: 428-433

Platelets loss Allogeneic Collections Flommersfeld et al. Trans. Apher Sci 2013, 49, 428-433

Post Collection Donor Issues Platelets (cont.) After 2 collections, plt <100,000 in 20-23% of donors Delayed plt recovery: start to rise only >2 days; return to baseline 7-10 days post collection Donors with low platelet counts are at potential risk from bleeding and remain at risk for up to 1 week Always consider other/additional cause e.g. Heparin Induced Thrombocytopenia Transf Apheresis Sci 2005;33:275 BMT 1999;24:1273 Blood 2009:113:3604

Being Compliant w/the Standard (3) FACT standard C8.5.1 & AABB 5.12.4: A CBC, including platelet count, shall be performed within 24 hours prior to each HPC collection by apheresis. C8.5.2: There shall be peripheral blood count criteria to proceed with collection.

Conclusions Cellular therapy standards ensure high quality products - standardize processes related to collection, processing & administration The different sets of the standards have similarities - Based on scientific literature, clinical practice and regulations Understanding the rationale behind the standards can help with compliance

Thank you!